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Abstract
PIK3CA upregulation, amplification and mutation have been widely reported in ovarian cancers and other tumors, which
strongly suggests that PIK3CA is a promising therapeutic target. However, to date the mechanisms underlying PIK3CA
regulation and activation in vivo is still unclear. During tumorigenesis, host-tumor interactions may play a critical role in
editing the tumor. Here, we report a novel mechanism through which the tumor microenvironment activates the PIK3CA
oncogene. We show that PIK3CA upregulation occurs in non-proliferating tumor regions in vivo. We identified and
characterized the PIK3CA 59 upstream transcriptional regulatory region and confirmed that PIK3CA is transcriptionally
regulated through NF-kB pathway. These results offer a new mechanism through which the tumor microenvironment
directly activates oncogenic pathways in tumor cells.
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Introduction
Phosphatidylinositol-39 kinase (PI-3 kinase) is an intracellular
transducer with lipid substrate specificity implicated in a wide
range of cancer-associated signaling pathways involved in tumor
cell metabolism, survival and proliferation [1,2,3,4,5,6,7]. It is
recruited and activated by multiple receptor tyrosine kinases and
generates second messengers via phosphorylation of membrane
inositol lipids at the D3 position [3,8]. PI-3 kinase was first
recognized as putative oncogene because of its ability to bind
polyoma middle T antigen [9,10]. Molecular cloning of PI-3
kinases revealed a large and complex family that contains three
classes of multiple subunits and isoforms [3,8]. However, how each
subunit precisely contributes to the progress and maintenance of
cancer is largely unknown [3,5].
The PIK3CA gene encodes the catalytic subunit p110-alpha, one
of the three catalytic subunit proteins of the class IA PI-3 kinases
that are usually activated by growth factor receptor tyrosine
kinases. PIK3CA was identified as an avian retrovirus-encoded
oncogene that transforms chicken embryo fibroblasts [11].
Numerous recent studies indicate that PIK3CA and downstream
pathways are frequently targeted by genomic amplification,
mutation or overexpression in solid tumors including ovarian
cancer [12,13,14,15,16,17,18,19,20]. Previous studies on the
function of PIK3CA have predominantly focused on regulatory
circuitries within the cancer cell. In vitro, PIK3CA plays a critical
role in cell survival and proliferation [1,2,3,4,5,7]. However, to
date it remains unknown whether PIK3CA assumes diverse roles
depending on the state and/or the context in which the tumor cell
is found. Furthermore, it remains unclear how such roles of
PIK3CA might be affected by the tumor milieu.
Dynamic interactions between genetic deregulation in tumor
cells and reactive molecular and cellular changes in host cells
populating the tumor microenvironment play a critical role in
promoting malignant transformation and tumor progression and
growth [21,22]. Following the acquisition of critical genetic
alterations, tumor cells are subjected to metabolic/ischemic stress
and edit the surrounding microenvironment. In turn, host cells
serve to edit the tumor, promoting the selection of tumor cells that
benefit from tumor microenvironment influences. Innate and
adaptive immune response mechanisms to tumors culminating in
inflammation have received significant attention in this context, as
inflammation has been shown to promote cancer growth and
progression [23,24,25]. Tumor-associated leukocytes produce
numerous proangiogenic factors promoting tumor vascularization
[26,27,28,29]. Furthermore, nuclear factor kappa-B (NF-kB), a
critical transcriptional regulator of inflammation, has been shown
to play a critical role in inflammation-driven carcinogenesis and to
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promote tumor growth and progression [25,30,31,32,33,34,35]. It
has thus been postulated that the continuous and dynamic cross-
talk between tumor cells and host cells ensures the survival of
tumor cells and sustains tumor growth [21,22]. The mutual effects
of tumor-host interactions have been characterized with respect to
angiogenesis. However, how tumor-host interactions affect directly
tumor cells remains partly undetermined.
Epithelial ovarian cancer (EOC), the most common ovarian
malignancy, continues to be the leading cause of death among
gynecological malignancies [36]. The lack of preventive strategies,
early diagnostic methods and effective therapies to treat recurrent
ovarian tumors creates a pressing need to understand its pathogen-
esis and to identify molecular targets for both diagnosis and therapy
of EOC at different stage of disease progression [20,37,38,39,40,41].
In this study, we examined the expression of PIK3CA in vivo and its
relationship with the tumor microenvironment in human ovarian
cancer. The identification and characterization of the PIK3CA 59
transcriptional regulatory region (TRR) together with functional
validation experiments confirmed that PIK3CA is transcriptionally
regulated by the microenvironment, through inflammation and NF-
kB. These results offer a new mechanism through which the tumor
microenvironment directly activates oncogenic pathways in tumor
cells and promotes tumor growth.
Materials and Methods
Patients and Specimens
The specimens used in this study were collected at the
University of Pennsylvania and the University of Turin, Italy
[42]. Tissues were obtained after patients’ written consent under a
general tissue collection protocol approved by the institution’s
Institutional Review Board (IRB) of the University of Pennsylvania
and the University of Turin. All tumors were from primary sites,
and were collected at the time of debulking surgery from
previously untreated patients with stage III and IV ovarian
cancer. Samples were snap-frozen immediately and stored at
280uC. Specimens were collected under local Institutional review
board approval and processed under procedures approved by the
HIPAA act.
Cell Culture
Cells were cultured in DMEM medium (Invitrogen, Carlsbad,
CA) supplemented with 10% fetal bovine serum (FBS, Invitrogen).
In some experiments cells were incubated in media enriched with
recombinant human TNF-a (50 or 100 ng/ml, BD Bioscience,
San Jose, CA) for various times as indicated.
Total RNA Isolation and Quantitative Real-time RT-PCR
Total RNA was isolated from 100 to 500 mg of frozen tissue or
16106 cultured cells with TRIzol reagent (Invitrogen). After treat-
ment with RNase-free DNase (Invitrogen), total RNA was reverse-
transcribed using Superscript First-Strand Synthesis Kit for RT-
PCR (Invitrogen) under conditions defined by the supplier. cDNA
was quantified by real-time PCR on the ABI Prism 7900 Sequence
Detection System (Applied Biosystems). Human PIK3CA forward
primer: TCA AAGGAT TGGGCA CTT TT, and reverse primer:
GCC TCG ACT TGC CTA TTC AG. PCR was performed using
Sybr Green PCR Core reagents (Applied Biosystems, Foster City,
CA) according to manufacturer’s instructions. PCR amplification of
the housekeeping gene GAPDH was performed for each sample as
control for sample loading and to allow normalization among
samples. A standard curve was constructed with PCR-II TOPO
cloning vector (Invitrogen) containing the same inserted fragment
and amplified by the real-time PCR.
Tissue Microarray
The tissue microarray was constructed as described previously
[43,44]. In brief, tumors were embedded in paraffin and 5-mm
sections were stained with hematoxylin–eosin to select represen-
tative regions for biopsies. Four core tissue biopsies were obtained
from each specimen. The presence of tumor tissue on the arrayed
samples was verified on hematoxylin–eosin stained section.
Immunohistochemistry (IHC) and Image Analysis
IHC was performed using the VECTASTAIN ABC Kit as
described by the manufacturer (Vector, Burlingame, CA). We used
the following primary antibodies (all from BD Pharmingen unless
noted otherwise): rabbit anti-human Ki67 (1:200, DAKO,
Carpinteria, CA); rabbit anti-human cytokeratin (1:200, DAKO);
rabbit anti-human p65 (1:400, Santa Cruz, Santa Cruz, CA);
mouse anti-human p110a (1:250 or 1:50); rat anti-mouse CD31
(1:200); mouse anti-human HIF1A (1:200); mouse anti-human c-
Jun (1:200); rat anti-mouse CD11b (1:200). Antibodies were
incubated for 2 hrs at room temperature or overnight at 4uC. The
immunoreaction was visualized with 3,39-diaminobenzidine (Vec-
tor). Double immunofluorescent staining was performed as
previously described [45]. Briefly, sections were sequentially
incubated in 5% normal serum; primary antibodies for 2 hrs;
and fluorescent labeled secondary antibodies (Vector) for 30 min.
Sections were counterstained with DAPI before being inspected
under the fluorescent microscope. Images were collected through
Cool SNAP Pro color digital camera (Media Cybernetics, Silver
Spring, MD) and staining index was analyzed using Image-Pro
Plus 4.1 software (Media Cybernetics).
TUNEL Assay
The ApopTag peroxidase in situ detection kit (Intergen) was
used to visualize apoptotic cells in vivo and in vitro. The procedure
was performed according to manufacturer’s instruction. Briefly,
tumor tissue sections were fixed with 1% paraformaldehyde in
PBS, followed by cold ethanol and acetic acid post-fixation.
Following incubation with residues of digoxigenin nucleotide and
terminal deoxynucleotide transferase for one hr at 37uC, cells were
incubated with FITC-labeled anti-digoxigenin antibody.
Plasmids
The mouse PIK3CA cDNA was generously provided by Dr.
Roberts (Harvard University). Mammalian expression plasmid
pCDNA3 was from Invitrogen. To construct luciferase reporter
plasmids, 59TRRs of the human and mouse PIK3CA were
amplified from BAC or genomic DNA using Expand High
Fidelity PCR System (Roche, Indianapolis, IN) and inserted
upstream of the luciferase gene in pGL3-Basic vector (Promega,
Madison, WI). Sequences of 59TRR in all these reporter
constructs were verified by DNA sequencing.
59 Rapid Amplification of cDNA Ends (59RACE)
Total RNA was extracted with the RNeasy Mini RNA kit
(Qiagen, Valencia CA) and the 59 RACE system (Invitrogen) was
used. The 59 RACE PCR product was inserted into the TA
cloning system (Invitrogen).
Plasmid Transfection
Cells were seeded in 6-well plates at 36105 cells/well and grown
overnight to ,40% confluence prior to transfection. All plasmids
were transfected with FuGENE6 transfection reagent (Roche)
following the manufacturer’s instructions. To select neomycin-
resistant cells, 400 mg/ml neomycin (Invitrogen) was applied. For
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shRNA experiments, cells were transfected with siRNA expressing
pLTsuppressor1.0. In vitro experiments indicated that suppression
of PIK3CA mRNA persisted for up to 30 days. All transfection
experiments were done in triplicate and repeated at least twice
with different DNA isolates.
Luciferase Reporter Assay
Cells were seeded in 6-well plates at 36105 cells/well and
grown overnight to 40% confluence prior to transfection. To test
the promoter activity of PIK3CA, a total of 0.5 mg reporter
construct and 0.01 mg pRL-TK internal control (Promega) were
used for each transfection. All transfection experiments were done
in triplicate and repeated at least twice with different DNA
isolates. Forty-eight hours post-transfection, luciferase analysis was
performed on Luminoskan Ascent (Thermo-Labsystems, Wal-
tham, MA) using Dual-Luciferase Reporter Assay System
(Promega) according to the manufacturers’ instructions. For co-
transfection experiments, 1 mg of each pCMV-IkBa or pCMV-
IkBaM plasmid (CloneTech, Mountain View, CA) was used.
Electrophoretic Mobility Shift Assay (EMSA)
Nuclear extract from cells was prepared using NE-PER Nuclear
and Cytoplasmic Extraction Reagents plus Halt Protease Inhibitor
Cocktail Kit (Pierce, Rockford, IL) following the manufacturer’s
protocols and stored at 280uC until used. Recombinant NFkB
(p50) was ordered from Promega. 59-Biotin-labeled DNA oligos
containing the wild-type human PIK3CA NFkB binding site
(GACGTGGGGGATTTTTCGCGTA), mutated human
PIK3CA NFkB binding site (GACGTGGGCGATTTTTCGC-
GTA), scramble human PIK3CA NFkB binding site (TCAGATA-
Figure 1. PIK3CA is upregulated in non-proliferating tumor cells in vivo. A to C. Double immunostaining of p110a (green, FITC) and Ki67
(red, Texas Red) in human ovarian cancer B. High magnification of a region from A with low expression of p110a. p110a is expressed at low levels and
localizes to the cytoplasm of Ki67-positive tumor cells. C. High magnification of a region from A with high expression of p110a. p110a is expressed at
high levels and localizes to the plasma membrane in Ki67-negative tumor cells. D and E. Immunohistochemical localization of Ki67 allows for clear
identification of areas of proliferating and areas of non-proliferating tumor cells in vivo in 2008 ovarian xenograft tumors. E. High magnification of
area from D showing the boundary between a proliferating and a non-proliferating region. F to H. Strong expression and cell membrane localization
of p110a is only found in Ki67-negative areas. F. Section adjacent to D, stained with antibody against human p110a (1:250 dilution). G. High
magnification of area from F showing the boundary between proliferating and non-proliferating region. H. High magnification of area from G
showing membrane localization of p110a in the non-proliferating region. I. Immunostaining of human cytokeratin identifies tumor cells in
proliferating and non-proliferating areas in the 2008 xenograft model. The line traces the boundary between the two areas, as defined by Ki67
staining in adjacent section (see J). Both proliferating and non-proliferating regions are positive for human cytokeratin (FITC, green), indicating tumor
cells. Cell nuclei were counterstained with DAPI. J to L. Double p110a and Ki67 immunostaining maps PIK3CA activation in proliferating or non-
proliferating areas in 2008 xenograft tumors. J. Ki67 (red, Texas Red) and p110a (FITC, green) exhibit reciprocal expression. K and L. High
magnification of proliferating region (I) and non-proliferating region (H) from J.
doi:10.1371/journal.pone.0001758.g001
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GACGAGACTTGAGTC), wild-type control NFkB binding site
(AGTTGAGGGGACTTTCCCAGG) [35], mutated control
NFkB binding site (AGTTGAGGCGACTTTCCCAGG) were
synthesized and the two complementary oligos were annealed to
obtain the double-stranded probe. EMSA was performed using
LightShift Chemiluminescent EMSA Kit (Pierce). The nuclear
extract (or p50) and 30 fmol of labeled probe were incubated in the
106binding buffer plus 1 mg poly(dI–dC) in 20 ml reaction system
at room temperature for 20 min. The entire 20 ml binding
reaction was loaded on a 7.5% polyacrylamide gel and run at
room temperature in 0.256 TBE at 110 V for 1–1.5 h. The
electrophoresed binding reaction was then transferred to Bright-
Star-Plus positively charged Nylon membrane (Ambion, Austin,
TX) in Trans-Blot SD Semi-Dry Electrophoretic Transfer Cell
(Bio-Rad, Hercules, CA) at 15 V for 30 min and cross-linked in
UV Stratalinker 1800 (Stratagene, La Jolla, CA) at auto cross-link
level for 1 min. Detection of Biotin-labeled DNA probe was
performed strictly following the manufacturer’s protocol.
Chromatin Immunoprecipitation (ChIP)
ChIP assay to detect p65 binding on the human PIK3CA
promoter was performed using the Upstate ChIP assay kit
(Upstate, Charlottesville, VA) following the manufacturer’s
instruction. Sheared DNA was incubated at 4uC overnight with
2 mg immunoprecipitating rabbit polyclonal IgG antibody to p65
(Santa Cruz) or 2 mg normal rabbit control IgG. Input and
chromatin-immunoprecipitated DNA was used as PCR template
for detection of p65 binding on the promoter (with primers 59-
GCACCAAGACACTACCTTGAATC-39 and 59-CTCTGCAG-
TCCTTTGACTCACTT-39) or on the GAPDH promoter (with
primers 59-GACACCATGGGGAAGGTGAA-39 and 59-GAGT-
AGGGACCTCCTGTTTC-39) using the PCR Core kit (Roche).
Bioinformatics
A search for potential transcription factor binding sites on the
human and mouse PIK3CA 59TRRs were performed using the
program Mat Inspector V2.2 at http://www.genomatix.de/
online_help/help_matinspector/matinspector_help.html [46].
Statistics
Statistical analysis was performed using the SPSS statistics
software package (SPSS). All results were expressed as mean 6
SD, and p,0.05 was used for significance.
Results
PIK3CA is upregulated in non-proliferating regions in
ovarian cancer
To reveal spatial aspects of PIK3CA regulation in tumor in vivo,
we first examined the expression of p110a in human ovarian
cancer specimens. Interestingly, strong p110a expression was
mainly detected in groups of non-proliferating, Ki672 tumor cells
(Figure 1 A to C). In these cells, p110a was translocated to the cell
membrane (Figure 1 C). In contrast, Ki67+ regions exhibited low
Figure 2. p110a is overexpressed in non-proliferating tumor cells in vivo. A. Immunohistochemical staining of p110a using high primary
antibody concentration (1:50) reveals low expression of p110a diffusely in the cytoplasm of tumor cells in Ki67-positive (Ki67+) regions. B and C. High
magnification of non-proliferating (B) and proliferating (C) regions from A.
doi:10.1371/journal.pone.0001758.g002
Figure 3. PIK3CA is upregulated in undervascularized tumor areas in vivo. A. Double immunostaining of CD31 (red, Texas Red) and p110a
(green, FITC) in the 2008 xenograft model. Strong p110a staining is mainly detected in tumor regions located distant from capillaries. B. Triple
staining of p110a (red, Texas Red), Ki67 (blue, AMCA) and TUNEL (green, FITC) in the 2008 xenograft model.
doi:10.1371/journal.pone.0001758.g003
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expression of p110a, which was mainly located in the cytoplasm,
while only few Ki67+ cells exhibited p110a at the cell membrane
(Figure 1 B). A tissue microarray was used to further validate this
result in human ovarian cancer. In 18 of 30 (60%) tumors, strong
p110a expression (and membrane localization) was detected
mainly in Ki672 tumor regions, while in the other tumors strong
membrane p110a expression was either detected both in both
Ki672 and Ki67+ tumor cells (5/30, 16.7%); mainly in Ki67+
tumor cells (3/30,10.0%); or it was undetectable (4/30; 13.3%).
To further confirm this result, we investigated xenograft tumors
generated with the 2008 ovarian cancer cell line. The advantage of
this model is that distinct areas of proliferating and resting tumor
cells can be clearly identified in vivo by Ki67 staining (Figure 1 D
and E) [47]. Similarly to the reciprocal expression observed in the
human specimens, strong p110a expression was detected in tumor
cells only in Ki672, non-proliferating regions (Figure 1 F to H). In
these areas, p110a was mainly localized to the cell membrane
(Figure 1 H). Double staining confirmed that areas expressing
p110a were in fact populated by tumor cells, which expressed
cytokeratin, an epithelial tumor marker (Figure 1 I to K). With
increased primary antibody concentration (from 1:200 to 1:50),
weak p110a expression could also be detected in Ki67+ regions,
Figure 4. Identification and characterization of the human PIK3CA promoters. A. Illustration of the structure of human PIK3CA gene and its
59 upstream regulatory region. B. A region highly rich in GC is found in the PIK3CA 59TRR. C. Illustration of the primers used for mapping RT-PCR of
the PIK3CA transcriptional start site (SST). D. Results of mapping RT-PCR. There is no band between the forward primer F1 located upstream of the
SST and the reverse primer R located on exon 1 of PIK3CA. The right size bands could be detected between primer F2 or F3 (both located downstream
of SST) and reverse primer R. E. A small splicing variant is found in the 59UTR of human PIK3CA gene, which can also be detected by mapping RT-PCR
(primers F2 and R). F. Summarized results of the transcriptional activity of PIK3CA TRR fragments.
doi:10.1371/journal.pone.0001758.g004
Figure 5. Alignment of human and mouse PIK3CA transcriptional regulatory regions.
doi:10.1371/journal.pone.0001758.g005
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but p110a localized diffusely to the cytoplasm in these areas
(Figure 2). Thus, oncogene PIK3CA is significantly upregulated in
non-proliferating regions in human ovarian cancer in vivo. These
non-proliferating regions always lack blood vessel support and
contain numerous necrotic/apoptotic cells as well as rich
lymphocyte infiltrating (Figure 3).
Identification and characterization of the human and
murine PIK3CA promoters
To better understand the regulation signals contributing to
upregulation of PIK3CA in cancer, 59 upstream regulatory
sequences of the human PIK3CA gene were identified. 59-rapid
amplification of cDNA end (59RACE) was employed to identify
the transcription start site (TSS) of human PIK3CA (Figure 4A and
B). A 125 bp segment of the 59-untranslated region (UTR) and 2.3
Kbp of the TRR of human PIK3CA were cloned from human
bacterial artificial chromosome (BAC, clone number: PR11-
245C23). We found that the 59 upstream regulatory region of
human PIK3CA is located approximately 50 Kbp upstream of the
translation start codon site (Figure 4A). This region is highly rich in
GC (Figure 4B). Mapping RT-PCR further confirmed the TSS of
PIK3CA, and a small splicing variant was identified (Figure 4C to
E). The murine PIK3CA 59 upstream regulatory sequence was also
Figure 6. 59 upstream regulatory sequence of the human PIK3CA gene.
doi:10.1371/journal.pone.0001758.g006
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cloned by the same method, and was found to be 63.6% identity to
the human sequence (Figure 5) and to include a small intron.
To further characterize the transcriptional activity of the
promoter region, the entire 2.3 Kbp 59 TRR or incrementally
truncated promoter fragments were subcloned together with a 316
or a 150 bp transcript region into the pGL-basic reporter vector to
reveal luciferase expression (Figure 4F). Strong transcriptional
activity was localized to the 22,340 to 2159 bp region by
luciferase assay, while transcriptional activity significantly de-
creased after 2159 bp (Figure 4F).
Next, transcription factor binding sites were predicted on
human PIK3CA 59TRR in silico by GenomatiX (http://www.
genomatix.de/index.html). Binding sites for numerous stress-
associated transcription factors were found, including NF-kB;
hypoxia-inducible factor (HIF); heat-shock protein (HSP); and
activator protein 1 (AP1) (Figure 6). Thus, stress signals mediated
by these factors might regulate PIK3CA expression in non-
proliferating tumor cells in areas of decreased vascularization
and increased lymphocyte-infiltrating.
Expression and localization of candidate transcription
factors in situ
The expression and localization of three putative regulatory
factors that emerged from the above in silico analysis, HIF1a;
c-Jun, a member of the AP1 complex; and the p65 subunit of
NF-kB, were screened in 2008 xenografts. Because function of
these factors requires expression and nuclear translocation, we
considered strong expression and nuclear localization indirect
evidence of functional activation. Strong nuclear HIF1a expres-
sion was seen in patchy cell clusters in Ki672 regions. HIF1a
protein was also detected in Ki67+ regions, but it mainly localized
to the cytoplasm (Figure 7 A, D and G). c-Jun protein was strictly
expressed in the boundaries between Ki67+ and Ki672 regions,
where only nuclear staining was detected. Few scattered c-Jun-
positive cells could also be detected in Ki67+ regions, but nuclear
c-Jun was not seen in Ki672 regions (Figure 7 B, E and H). Strong
nuclear localization of NF-kB/p65 protein was seen in the Ki672
regions and in Ki67+ areas adjacent to the Ki672 regions
(Figure 7 C, F and I). Interestingly, strongest nuclear NF-kB/p65
was detected adjacent to areas of tissue necrosis (Figure 7 F). This
data together with the PIK3CA promoter analysis suggest that
HIF1a and NF-kB are implicated in the upregulation of PIK3CA
in Ki672 regions in vivo. Consistent with this hypothesis, the
hypoxia/HIF pathway has been reported to regulate PIK3CA in
cancer cells [48]. Since hypoxic regulation of PIK3CA has been
confirmed, we next focused on the regulation of PIK3CA by the
NF-kB pathway.
NF-kB binds to the promoter and upregulates PIK3CA
expression
Consistent with an important role of NF-kB in regulating
PIK3CA, we found NF-kB binding site consensus sequences in
Figure 7. Expression and localization of candidate transcription factors in situ. A to C. Immunohistochemical staining of candidate
transcription factors HIF1a, c-Jun and NF-kB in 2008 xenografts. The line shows the boundary between the Ki67+ p110a-low, and Ki672 p110a-high
regions. D to F. High magnification from A to C, respectively, shows expression and nuclear localization of HIF1A, c-Jun and NF-kB in 2008
xenografts. G to I. Illustration of the localization of the candidate transcription factors HIF1a, c-Jun and NF-kB in the 2008 xenograft model. Large
dots represent cytoplasmic localization, while small dots represent nuclear localization. The line represents the boundary between the Ki67+ p110a-
low, and Ki672 p110a-high regions.
doi:10.1371/journal.pone.0001758.g007
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human and mouse PIK3CA 59TRRs (Figure 8A). The human
promoter NF-kB binding site was located at 2807 to 2786 bp.
We tested whether NF-kB regulates the transcriptional activity of
human PIK3CA promoter in vitro. NF-kB activation requires
release from its inhibitory subunit IkBa, which allows NF-kB
translocation to the nucleus [34,35]. Transient forced expression
of wild-type IkBa or mutant IkBa (IkBaM), both of which bind
NF-kB and block its translocation to the nucleus, attenuated the
transcriptional activity of PIK3CA promoter, as revealed by
luciferase assay. Removing the NF-kB binding site from the
promoter region abrogated the inhibitory activity of IkBa or
IkBaM (Figure 8 B and C).
The predicted NF-kB binding sequence in the human PIK3CA
promoter was further tested using gel shift assay. Nuclear proteins
from 2008 ovarian cancer cell line treated with TNF-a were able
to shift (bind) oligonucleotide sequences containing the predicted
NF-kB binding site of human PIK3CA promoter, but were not able
to shift either mutant or mock oligonucleotide sequences (Figure 8
D). In addition, recombinant NF-kB/p50 protein was able to shift
the oligonucleotide sequences containing the predicted NF-kB
binding sites, confirming their presence in the human PIK3CA
promoter (Figure 8 E). Finally, the presence of NF-kB binding site
in the PIK3CA promoter was confirmed by chromosome
immunoprecipitation assay (ChIP).
Inflammation might regulate PIK3CA expression via NF-
kB pathway
During tumor growth, metabolic/ischemic stress induces tumor
cell death, recruiting inflammatory cells including macrophages.
These release proinflammatory cytokines which activate the NF-
kB pathway [25,33,34,35]. We mapped the distribution of
necrosis, tumor-infiltrating macrophages and activation of NF-
kB in the 2008 xenograft model. Morphologic necrosis was
detected predominantly in Ki672 p110a+ regions, often located
in their center (Figure 9 A). Brisk infiltration of CD11b+
macrophages, which produce pro-inflammation cytokines such
as TNF-a, was found in association with areas of necrosis (Figure 9
B to D).
TNF-a one of major cytokines produced by tumor-associated
macrophages, is known to activate NF-kB. Because murine TNF-a
is 69% identical and 85% homologous to human TNF-a, and it is
known to bind to the human TNF-a receptor with the same
affinity and to produce similar biologic effects on human cells as
human TNF-a [49,50,51], we hypothesized that macrophage-
Figure 8. NF-kB binds to the PIK3CA promoter and activates its expression. A. Illustration of the predicted NF-kB binding site in human (top)
or murine (bottom) PIK3CA promoter region. B. Illustration of the constructs comprising luciferase linked to the human PIK3CA promoter with (Luc-
2340/316) or without the NF-kB binding site (Luc-378/316). C. Summary of luciferase activities of Luc-2340/316 and Luc-378/316 co-transfected with
pCMV- IkBa or pCMV- IkBaM. D. Gelshift assay using ovarian cancer cell nuclear extract after TNF-a stimulation. Lane 1, NF-kB binding site of wild-
type human PIK3CA promoter (wt huPIK3CA NF-kB probe) alone; lanes 2 and 3, wt huPIK3CA NF-kB probe+nuclear extract; lane 4, control NF-kB
probe+nuclear extract, lanes 5 and 6, mutated huPIK3CA NF-kB probe+nuclear extract; lane 7, mutated control NF-kB probe+nuclear extract; lanes 8
and 9, scramble huPIK3CA NF-kB probe+nuclear extract. E. Gel shift assay using recombinant NF-kB/p50 protein. Lane 1, wt huPIK3CA NF-kB probe
alone; lanes 2 and 3, wt huPIK3CA NF-kB probe+p50; lane 4, mutated huPIK3CA NF-kB probe alone; lanes 5 and 6, mutated huPIK3CA NF-kB
probe+p50; lane 7, control NF-kB probe alone; lanes 8 and 9, control NF-kB probe+p50.
doi:10.1371/journal.pone.0001758.g008
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derived TNF-a could be in part responsible for the observed NF-
kB activation and PIK3CA upregulation in 2008 tumors cells in
vivo. First, we tested whether TNF-a increases NF-kB complex
binding to the PIK3CA promoter using the ChIP assay. Antibody
to NF-kB/p65 was able to precipitate the PIK3CA promoter
sequence and this was increased in a time-dependent manner by
TNF-a treatment, which increases NF-kB translocation to the
nucleus (Figure 9E). Thus, the PIK3CA promoter contains a
functional NF-kB binding site and can be activated by NF-kB.
Lastly, we tested whether TNF-a increased PIK3CA mRNA
expression in ovarian cancer cell lines in vitro. A significant
upregulation of PIK3CA was found in two ovarian cancer cell lines
(Figure 9F). Taken together, our results indicate that inflammation
triggered in response to tumor cell death might one of the
mechanisms that upregulate PIK3CA expression via NF-kB in
ovarian cancer cells in vivo.
Discussion
PI-3 kinases are intracellular lipid kinases implicated in the
regulation of cell metabolism, survival and proliferation
[1,2,3,4,5]. In this study, we characterized the expression and
transcriptional regulation of PIK3CA in human ovarian caner in
vivo. We reported the spatial dissociation between tumor cell
proliferation and PIK3CA upregulation, and a specialized func-
tional role of PIK3CA in non-proliferating tumor cells in vivo. The
identification and characterization for the first time of the PIK3CA
59 upstream regulatory region confirmed that PIK3CA is an
important mediator of tumor cell response to stress in vivo and
enabled the identification of a molecular link between inflamma-
tion and tumor growth mediated by NF-kB and p110a.
Based on in silico prediction and in situ scanning, at least two
stress signaling pathways appeared to play important roles in
Figure 9. TNF-a regulates PIK3CA expression via NF-kB pathway. A. H&E staining of 2008 tumor reveals a prominent area of necrosis (N). B
and C. Immunohistochemical staining of murine CD11b reveals macrophage infiltrate in a 2008 xenograft. CD11b+ cells infiltrate tumors in Ki67-
negative regions in proximity of necrosis. C. High magnification from B. D. Double immunostaining of CD11b (green, FITC) and Ki67 (red, Texas Red)
reveals CD11b+ macrophages mainly in non-proliferating Ki67-negative regions. E. ChIP analysis of NF-kB binding to the endogenous PIK3CA
promoter. The arrows indicate the positions of the primers flanking 2803 NF-kB binding site that were used in the ChIP assays. Cells were treated
with TNF-a for 0, 30, or 90 min, and then chromatin protein-DNA complexes were cross-linked using formaldehyde. The purified nucleoprotein
complexes were immunoprecipitated with p65 antibody or non-immune IgG and amplified by PCR. F. PIK3CA mRNA expression levels after
stimulation with pro-inflammatory cytokine TNF-a. G. Illustration of the transcriptional regulation of PIK3CA by NF-kB.
doi:10.1371/journal.pone.0001758.g009
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PIK3CA regulation in cancer, namely HIF and NF-kB. HIF
binding sites were identified in the PIK3CA promoter region and
strong nuclear HIF staining was detected in the areas where tumor
cells upregulate PIK3CA in vivo. This is in agreement with recent
evidence that PIK3CA is upregulated by hypoxia in renal
carcinoma cell lines [48]. The second regulatory pathway
mediated by NF-kB was characterized in this study. We confirmed
NF-kB binding sites on the PIK3CA promoter by gel shift;
documented binding of NF-kB through ChIP; and showed
increased binding of NF-kB to the PIK3CA promoter by TNF-a.
The use of the 2008 xenograft model enabled us to confirm that
activation of NF-kB coincides with p110a upregulation in non-
proliferating tumor cells in vivo.
NF-kB plays a critical role in inflammation-driven tumor
formation, growth, and progression [25,30,31,32,33,34,35]. In the
classical pathway, NF-kB activation is triggered in response to
proinflammatory cytokines that lead to phosphorylation-induced
IkB degradation and liberation of NF-kB p50:RelA or p50:c-Rel
dimers [25,35]. NF-kB activation promotes transcription of
diverse genes encoding inflammatory cytokines, growth factors
and cell adhesion molecules, which can promote tumor growth.
Importantly, NF-kB activation may also promote tumor cell
survival directly through inhibition of apoptosis or necrosis [34].
The present data offers the evidence that NF-kB directly
upregulates PIK3CA and provides a novel pathway through which
NF-kB activation can promote cancer cell survival during stress.
Interestingly, activation of the PI-3 kinase/Akt/mTOR pathway
has been previously shown to suppress autophagy and direct
apoptosis-resistant tumor cells under stress to necrotic cell death,
which results in inflammation and accelerated tumor growth [52].
The present results provide novel in vivo evidence to support the
concept that tumor-host interactions contribute to oncogene
activation and tumor growth. Based on these findings and
previously reported evidence, we propose a novel model to
interpret the function of PIK3CA in solid tumors and its regulation
by the tumor microenvironment (Figure 9G). During tumor
growth, PIK3CA may be expressed at low levels and p110a
localizes mainly to the cytoplasm in cancer cells proliferating in
proximity to vessels in a metabolically lush microenvironment.
This ‘‘physiologic’’ level of PIK3CA expression serves as an
intracellular mediator maintaining tumor cell proliferation and
growth by responding to extracellular growth factors. As tumor
cells outgrow nutrient support, cancer cells are subjected to
metabolic/ischemic stress ultimately leading to cell death. The
paracrine factors released by stressed cells as well as infiltrating-
leucocytes can edit the microenvironment towards inflammation.
Our data suggest that the inflammatory microenvironment can
edit back the tumor cells through activation of the NF-kB/PIK3CA
pathway, with multifaceted results that promote survival.
In summary, we demonstrated a specialized upregulation of
PIK3CA oncogene in non-proliferating tumor cells induced by the
microenvironment through inflammation. Non-proliferating tu-
mor cells may contribute to resistance to current cancer
therapeutics and could be an important source for tumor
recurrence. Isoform-specific targeting of PIK3CA by small
molecule inhibitors or siRNA can significantly block tumor growth
and induce apoptosis in human cancer cells [53]. Thus, PIK3CA-
targeted cancer therapy might be a rational approach to target
non-proliferating tumor cells and enhance the effect of chemo-
therapy or radiation in combinatorial therapy. Furthermore, based
on our results, PIK3CA targeting might be a rational approach to
combine with anti-inflammatory cancer therapy.
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